Viking Therapeutics Files 8-K
Ticker: VKTX · Form: 8-K · Filed: Nov 4, 2024 · CIK: 1607678
Sentiment: neutral
Topics: 8-K, SEC filing, disclosure
Related Tickers: VKTX
TL;DR
Viking Therapeutics filed a routine 8-K, no major news yet.
AI Summary
On November 4, 2024, Viking Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements and Exhibits. No specific material events or financial figures were detailed in the provided excerpt, suggesting it may be a routine filing or related to ongoing disclosures.
Why It Matters
This filing indicates Viking Therapeutics is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a standard procedural disclosure without any immediate negative or positive material information.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- November 4, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- San Diego, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Viking Therapeutics?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was this 8-K report filed?
The report was filed on November 4, 2024.
What is Viking Therapeutics' state of incorporation?
Viking Therapeutics, Inc. is incorporated in Delaware.
Where are Viking Therapeutics' principal executive offices located?
The principal executive offices are located at 9920 Pacific Heights Blvd, Suite 350, San Diego, California.
Does this filing announce any new material events or financial results?
The provided excerpt does not detail any specific new material events or financial results, suggesting it may be a routine or procedural filing.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-11-04 06:31:16
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20241104.htm (8-K) — 43KB
- vktx-ex99_1.htm (EX-99.1) — 152KB
- img201808844_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-120267.txt ( ) — 332KB
- vktx-20241104.xsd (EX-101.SCH) — 30KB
- vktx-20241104_htm.xml (XML) — 5KB
01. Regulation FD
Item 7.01. Regulation FD On November 4, 2024, Viking Therapeutics, Inc. issued a press release announcing results from its oral Phase 1 single ascending dose and multiple ascending dose clinical trial of VK2735 and follow-up results from its Phase 2 VENTURE clinical trial of VK2735 demonstrating the treatment's longer-term maintenance effects and pharmacokinetic information. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information furnished under this Item 7.01 (Regulation FD Disclosure) of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated November 4, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIKING THERAPEUTICS, INC. Date: November 4, 2024 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)